Table 4.

inhibitors and drugs targeting collagen modifications

Therapy target	Name drug	Drug format	Disease	Research stage
P4HA1	Diethyl-pythiDC	Small molecule inhibitor	Colorectal cancer	Preclinical [131]
P4HA2	Aspirin	Small molecule inhibitor	Hepatocellular carcinoma	Preclinical [132]
P4H	EDHB	Small molecule inhibitor	Breast cancer	Preclinical [160]
BMP1.3	Anti-BMP1.3	mAb	Myocardial infarction	Preclinical [134]
LOX	BAPN (β-aminopropionitrile) PXS-5505	Irreversible inhibitor Small molecule inhibitor	Cancer Pancreatic cancer	Preclinical [139] Preclinical [161]
LOXL2	Simtuzumab GS341	mAb pAb	Fibrosis, Cancer	Phase II [162] Preclinical [135, 163]
LOXL2	PXS-S1A PXS-S2A PAT-1251 PXS-5382A Epigallocatechin gallate (EGCG)	Small molecule inhibitors	Fibrosis, heart failure, glaucoma, oncological and angiogenic diseases	Phase II [135] Phase II [135] Phase I [164, 165] Phase I [135] Phase I [166]
Copper	tetrathiomolybdate (TM)I d-penicillamine (D-pen)	Copper chelators	Cancer Breast cancer	Phase I/II [140, 141, 167] Phase II [136, 168]
Dual LOX/LOXL	PXS-5153A CCT365623	Inhibitor	Fibrosis Cancer	Preclinical [169] Preclinical [170, 171]
MMP9 MMP9 MMP14 MMP1, MMP2, MMP3	Andecaliximab (GS-5745) AB0041, AB0046, DX-2400 Single Chain Fragment Variables	mAb mAb mAb mAb	Cancer, Colorectal cancer Breast, melanoma, sarcoma Breast cancer	Phase III [172, 173] Preclinical [144, 174] Preclinical [175] Preclinical [176]
PAD4 PAD4 PAD4 PAD4	TDFA TDCA Cl-amidine F-amidine GSK199, GSK484 JBI-589	Selective Irreversible small molecule inhibitors Reversible inhibitors Small molecule	Inflammatory disorders and Cancer Cancer	Preclinical [177] Preclinical [178, 179] Preclinical [177] Preclinical [114]